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Abstract
Objectives This study aimed to investigate changes in
levels of biomarkers associated with adipocyte function
and insulin and glucagon kinetics after a meal tolerance
test (MTT) during treatment with dapagliflozin among
obese type 2 diabetes mellitus (T2DM) patients.
Methods T2DM patients with hemoglobin A1c (HbA1c)
levels [6.5 % and body mass index (BMI) [25 kg/m2
were treated with dapagliflozin 5 mg/day for at least
12 weeks. HbA1c, body weight, ketone bodies, adipo-
nectin, plasminogen activator inhibitor-1 (PAI-1), and
C-reactive protein (CRP) were measured before and after
treatment with dapagliflozin. A subset of patients under-
went an MTT.
Results Of 27 participating patients (mean age 47.9 years;
17 males), five were drug-naive and 22 were treated with
other antidiabetic agents, including insulin and glucagon-like
peptide-1 (GLP-1) receptor agonists. Following treatment
with dapagliflozin, HbA1c levels significantly improved
(7.44 ± 0.56 to 6.70 ± 0.0.57 %; p\ 0.01), body weight
significantly decreased (90.9 ± 16.5 to 87.1 ± 15.9 kg;
p\ 0.01), ketone bodies increased, adiponectin significantly
increased, and high-sensitivity CRP tended to decrease.
During the MTT, blood glucose DAUC2 significantly
decreased, glucagon DAUC2 increased, and immunoreactive
insulin (IRI) did not change in 11 of 27 patients.
Conclusion Although ketone bodies increased significantly,
adiponectin increased and high-sensivity CRP decreased
significantly. These findings suggest that sodium-glucose
cotransporter-2 (SGLT2) inhibitors may potentially improve
adipocyte function in treating obese T2DM patients.
Key Points
Treatment of obese type 2 diabetes mellitus (T2DM)
patients with dapagliflozin 5 mg once daily for
12 weeks significantly improved HbA1c levels and
body weight to the same level as previous reports.
Although ketone bodies increased significantly,
high-sensitivity C-reactive protein significantly
decreased, while adiponectin significantly increased.
During the meal tolerance test, blood glucose D area
under the curve from time zero to 2 h (AUC2)
reduced significantly, but glucagon DAUC2
increased, while immunoreactive insulin did not
differ.
1 Introduction
Type 2 diabetes mellitus (T2DM) is a metabolic disorder
associated with high blood glucose levels. Its pathology
involves insulin resistance in adipocytes and skeletal
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muscle, and insulin hyposecretion from pancreatic b cells
[1]. Sustained hyperglycemia is a strong risk and acceler-
ative factor for macroangiopathy and microangiopathy [2].
Both the American Diabetes Association and the Japanese
Diabetes Society recommend achieving a hemoglobin A1c
(HbA1c) level of \7 % as a therapeutic goal since the
adequate control of blood glucose is associated with the
prevention of micro- and macro-atherosclerotic complica-
tions [3, 4].
The treatment of T2DM typically involves the use of
antidiabetic agents, as well as diet and exercise therapy. In
2013, the Japan Diabetes Clinical Data Management Study
Group (JDDM) reported that, in Japan, the average HbA1c
level was 6.96 % in patients with T2DM [5], which sug-
gests that half of the T2DM patients in Japan failed to
achieve their therapeutic goal and needed to undergo fur-
ther aggressive treatment. In particular, only one-third of
patients treated with insulin or a glucagon-like peptide-1
(GLP-1) receptor agonist met the goal of an HbA1c level
\7 % [5], suggesting that supplemental or add-on therapy
might be needed to better manage T2DM.
Kidneys play a key role in maintaining blood glucose
levels via glycogenesis, glucose filtration at glomeruli, and
reuptake of glucose at the tubules [6]. Almost the entire
amount of glucose filtered by the tubules is actively reab-
sorbed by sodium glucose transporters (SGLT) in the
proximal tubule. Sodium-glucose cotransporter-2 (SGLT2)
inhibitors decrease renal glucose reabsorption; the
remaining filtered glucose is reabsorbed by SGLT1 at the
descending proximal tubule [7, 8]. An increase in SGLT2
expression at the proximal tubule has been reported in
T2DM patients [9], and this increased expression has been
suggested to be causally associated with increased glucose
levels in T2DM.
Given the foregoing, compounds that inhibit SGLT2
have been targeted and developed as agents to treat T2DM.
Dapagliflozin, one such SGLT2 inhibitor, was introduced
into clinical practice in Japan in 2014. SGLT2 inhibitors
reduce blood glucose levels by increasing the amount of
glucose excreted into urine [10]. It is anticipated that these
inhibitors will become one of the basic tools for treating
T2DM since hypoglycemia occurs less often when com-
pared with using existing antidiabetic agents, and their
mechanisms of action also differ. Despite this, few studies
have examined the effects of SGLT2 inhibitors, including
their influence on insulin and glucagon kinetics and
biomarkers associated with adipocyte function in clinical
settings in Japan.
To this end, we investigated changes in levels of
biomarkers associated with adipocyte function and insulin
and glucagon kinetics after a meal tolerance test (MTT)
during treatment with dapagliflozin.
2 Subjects and Methods
2.1 Subjects
Outpatients with T2DM who visited a medical clinic
(Okamoto Medical Clinic) that specializes in diabetes
treatment in Tokyo, Japan, from June 2014 to December
2014, were screened. On a monthly basis, approximately
980 outpatients visited the medical clinic, and approxi-
mately 92 % were diabetic patients. Mean age and HbA1c
were 57.4 years and 7.4 %, respectively, and proportions of
diabetic retinopathy and nephropathy were 21.7 and
32.6 %, respectively.
Among these patients, those who satisfied the follow-
ing inclusion criteria were eligible for enrollment: (1)
HbA1c level C6.5 %, despite treatment with only diet and
exercise therapy or treatment with a combination of
antidiabetic agents, including insulin and GLP-1 receptor
antagonists, and diet and exercise therapy for at least
3 months prior to the study period; (2) body mass index
(BMI) [25 kg/m2; and (3) age C20 years. Patients with
type 1 diabetes mellitus, severe cardiovascular diseases,
renal disease with an estimated glomerular filtration rate
(eGFR) of \60 mL/min/1.73 m2, severe liver disorder,
dementia, and/or a malignant tumor were excluded from
the study.
2.2 Study Design
This was a single-arm interventional study. In additing with
present treatment, dapagliflozin 5 mg (Forxiga; ONO
Pharmaceutical Co., Ltd, Osaka, Japan) was administered
orally once daily in the morning for at least 12 weeks. The
dosages of concomitant agents did not change during
treatment with dapagliflozin. Blood samples were collected
at fasting in the morning to measure levels of HbA1c,
serum creatinine, ketone bodies (acetoacetic acid, 3-hy-
droxybutyric acid, and total ketone), high-sensitivity
C-reactive protein (hs-CRP), adiponectin, and plasminogen
activator inhibitor-1 (PAI-1). Physical characteristics and
body weight were also assessed.
In a subset of patients, the MTT was performed before
and after treatment with dapagliflozin. The test meal (total
calories, 491.5 kcal; carbohydrate, 75 g; fat, 11.5 g; pro-
tein, 11.5 g) was prepared by a meal delivery company
(Seven-Eleven Japan Co., Ltd, Tokyo, Japan) according to
recommendations of the Japanese Diabetes Society. The
MTT was initiated at 9:00 am, and patients ate the test meal
within 15 min. Blood samples were collected immediately
before and 1 and 2 h after finishing the test meal, for
simultaneous measurement of blood glucose, immunore-
active insulin (IRI), and glucagon levels.
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2.3 Assessments
The primary endpoint was change in HbA1c level at
12 weeks after treatment with dapagliflozin, measured
using National Glycohemoglobin Standardization Program
(NGSP) values, and the secondary endpoint was change in
adiponectin and PAI-1 levels from baseline at 12 weeks
after treatment with dapagliflozin. In addition to these
assessments, changes in glucagon and insulin levels after
the MTT were also investigated as a secondary endpoint.
Homeostasis model assessment–insulin resistance
(HOMA–IR) and homeostasis model assessment–b-cell
function (HOMA–b) were calculated using the following
equations: HOMA–IR = [fasting IRI (lU/mL) 9 fasting
blood glucose level (mg/dL)]/405; HOMA–b = [360 9
fasting IRI (lU/mL)]/[fasting blood glucose level (mg/
dL)] - 63 [11]. eGFR was calculated using the Japanese
GFR equation: eGFR (ml/min/1.73 m2) = 194 9 Cr -
1.094 9 age - 0.287 (90.739 if female).
2.4 Statistical Analysis
Data are presented as mean ± standard deviation (SD) for
continuous variables, and number and percentage for cate-
gorical variables. To assess potential factors that modify
adipocyte function, univariate linear regression analysis
was performed among changes in continuous variables, at
12 weeks after treatment from baseline. Multivariate linear
regression analysis was also performed for changes in adi-
ponectin or PAI-1 as the response variable, and changes in
other parameters (HbA1c, body weight, eGFR, total ketone,
and hs-CRP) as predictor variables. The area under the
curve from time zero to 2 h (AUC2) during the MTT was
calculated to evaluate changes in blood glucose, IRI, and
glucagon levels. For paired analysis, the Wilcoxon signed-
rank test was used for continuous variables. All statistical
analyses were performed using the Statistical Package for
JMP 10 (SAS Institute Inc., Cary, NC, USA). All reported
p values were two-sided (significance level 0.05).
The study protocol was reviewed and approved by the
Council of Okamoto Medical Clinic, and all procedures
followed were in accordance with ethical standards of the
responsible committees on human experimentation (insti-
tutional and national) and with the Helsinki Declaration of
1975, as revised in 2000 and 2008. Informed consent was
obtained from all patients in the study.
3 Results
During the study period, 27 patients were treated with
dapagliflozin for 12 weeks and had blood samples taken.
Patient characteristics at baseline are summarized in
Table 1. Mean age was 47.9 ± 8.8 years, and 17 patients
(63.0 %) were male. Mean BMI at baseline was
32.7 ± 6.5 kg/m2. Five patients (18.5 %) were being
treated with only diet and exercise therapy, and 22 patients
had been previously treated with other antidiabetic agents.
The mean number of coadministered agents was 2.5 ± 1.3
(range 1–5), and four patients had been receiving diuretics
during the study period. Serum potassium did not show any
significant change, from 4.2 ± 0.4 to 4.2 ± 0.4 mEq/L
(p = 0.87), and serum sodium slightly, but significantly,
decreased from 142.0 ± 2.1 to 141.0 ± 2.3 (p\ 0.05)
(Table 2).
Changes in the assessed parameters are shown in
Table 2. Mean HbA1c and mean body weight significantly
decreased by 0.75 ± 0.38 % (p\ 0.01) and 3.8 ± 3.2 kg
(p\ 0.01), respectively, after treatment with dapagliflozin.
While eGFR did not significantly change, levels of ketone
bodies significantly increased after treatment with dapa-
gliflozin. Moreover, hs-CRP significantly decreased and
PAI-1 showed no significant change after treatment with
dapagliflozin. Interestingly, adiponectin slightly, but sig-
nificantly, increased after treatment.
In the univariate linear regression analysis, inverse
correlations were found between changes in HbA1c
level/body weight and change in adiponectin level, and
positive correlations were found between changes in
HbA1c level/body weight and change in adiponectin level
(Table 3). Multivariate linear regression analysis revealed
inverse change in HbA1c level and body weight to be
strong contributors to change in adiponectin level
(Table 4).
Among the 11 patients who underwent the MTT (male
proportion 72.7 %, mean age 49.1 ± 7.8 years), mean
HbA1c level decreased from 7.28 ± 0.46 to
6.52 ± 0.45 %, but HOMA–IR and HOMA–b did not
significantly change, after treatment with dapagliflozin
Table 1 Patient characteristics at baseline (N = 27)
N (%) or mean ± SD
Sex, men 17 (63.0)
Age, years 49.7 ± 8.8
Body mass index, kg/m2 32.7 ± 6.5
Oral hypoglycemic agents, yes 22 (81.5)





GLP-1 receptor agonist 3 (11.1)
SD standard deviation, DPP-4 dipeptidyl peptidase 4, GLP-1 gluca-
gon-like peptide-1
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(2.53 ± 1.68 to 2.33 ± 1.52, p = 0.68, and 38.4 ± 25.4 to
21.0 ± 14.6, p = 0.06, respectively). Figure 1 shows the
time-dependent changes in blood glucose, IRI, and gluca-
gon levels after the MTT. Mean blood glucose at 2 h after
the MTT reduced significantly compared with baseline,
whereas a significant increase was observed for glucagon.
IRI did not change after the MTT compared with baseline.
Figure 1 shows changes in blood glucose, IRI, and
glucagon levels after the MTT, before and 12 weeks after
treatment with dapagliflozin. Blood glucose at baseline and
Table 2 Comparison of
measurements between baseline
and 12 weeks after treatment
with dapagliflozin (N = 27)
Baseline 12 weeks Change p value
HbA1c (%) 7.44 ± 0.56 6.70 ± 0.57 -0.75 ± 0.38 \0.01
Body weight (kg) 90.9 ± 16.5 87.1 ± 15.9 -3.8 ± 3.2 \0.01
eGFR (mL/min/1.73 m2) 91.6 ± 22.3 89.5 ± 21.9 -2.1 ± 8.1 0.19
Sodium (mEq/L) 142.0 ± 2.1 141.0 ± 2.3 -1.0 ± 0.2 \0.05
Potassium (mEq/L) 4.2 ± 0.4 4.2 ± 0.4 0 ± 0 0.87
Acetoacetic acid (lmol/mL) 22.1 ± 9.6 35.5 ± 26.9 13.4 ± 29.61 \0.01
3-hydroxybutyric acid (lmol/mL) 38.2 ± 14.4 73.9 ± 69.0 35.7 ± 68.3 \0.01
Total ketone bodies (lmol/mL) 60.3 ± 20.8 109.4 ± 94.7 49.1 ± 94.1 \0.01
High-sensitivity CRP (ng/mL) 2410 ± 2814 1607 ± 1960 -803 ± 1080 \0.01
Adiponectin (lg/mL) 5.1 ± 2.3 6.7 ± 4.2 1.7 ± 2.7 \0.01
PAI-1 (mg/mL) 30.0 ± 16.8 26.8 ± 30.1 -3.2 ± 32.5 0.07
Data are expressed as mean ± standard deviation
HbA1c hemoglobin A1c, eGFR estimated glomerular filtration rate, CRP C-reactive protein, PAI-1 plas-
minogen activator inhibitor-1
Table 3 Correlation
coefficients by univariate linear




DBody weight -0.696a 0.435a
DeGFR 0.206 0.039
DAcetoacetic acid -0.107 -0.113
D3-hydroxybutyric acid -0.157 -0.063
DTotal ketone bodies -0.145 -0.078
DHigh-sensitivity CRP 0.106 -0.066
DAdiponectin - -0.326
D Difference from baseline to endpoint (12 weeks after treatment with dapagliflozin)
HbA1c hemoglobin A1c, eGFR estimated glomerular filtration rate, CRP C-reactive protein
a p\ 0.05
Table 4 Coefficients by
multivariate linear regression




activator inhibitor-1 (R2 = 0.243)
DHbA1c -0.5085a 1.7003
DBody weight -2.2729a 33.1321
DeGFR 0.0470 0.3167
DTotal ketone bodies -0.0003 -0.0539
DHigh-sensitivity CRP -0.0001 0.0019
D Difference from baseline to endpoint (12 weeks after treatment with dapagliflozin)
HbA1c hemoglobin A1c, eGFR estimated glomerular filtration rate, CRP C-reactive protein
a p\ 0.05
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1 and 2 h after the test meal reduced significantly with
dapagliflozin treatment [7.57 ± 0.69 vs. 7.05 ± 0.70
mmol/L (136.2 ± 12.4 vs. 126.9 ± 12.7 mg/dL), p\
0.05; 12.17 ± 1.62 vs. 10.51 ± 0.93 mmol/L (219.1 ±
29.1 vs. 189.1 ± 16.7 mg/dL), p\ 0.01; 11.53 ± 2.59 vs.
8.79 ± 1.42 mmol/L (207.5 ± 46.6 vs. 158.3 ± 25.6 mg/
dL), p\ 0.01, respectively]. There was no difference in
IRI at baseline and 2 h after the test meal, although it was
reduced by 1 h after the test meal. Glucagon significantly
increased with dapagliflozin treatment at baseline and 1
and 2 h after the test meal (149.5 ± 28.6 vs. 173.7 ± 22.5
pg/mL, p\ 0.01; 144.0 ± 33.7 vs. 173.1 ± 16.4 pg/mL,
p\ 0.05; 136.2 ± 27.8 vs. 170.0 ± 26.3 pg/mL, p\ 0.01,
respectively).
Blood glucose AUC2 decreased significantly during the
MTT (391 ± 51 to 287 ± 28 mg/dLh, p = 0.01), but IRI
AUC2 did not change (49.5 ± 35.2 to 36.9 ± 24.4 lU/
mLh, p = 0.85). On the other hand, glucagon AUC2
increased significantly (287 ± 58 to 345 ± 38 pg/dLh,
p = 0.04).
No severe adverse reactions (e.g. hypoglycemia, renal
dysfunction, urinary tract infection, dehydration, and
ketoacidosis) were observed in patients after dapagliflozin
treatment.
4 Discussion
Treatment of obese T2DM patients with dapagliflozin
5 mg once daily for 12 weeks significantly improved dia-
betic control and reduced body weight to the same level as
previous reports. Although ketone bodies significantly
increased, hs-CRP significantly decreased and adiponectin
significantly increased. During the MTT, blood glucose
DAUC2 reduced significantly, but glucagon DAUC2
increased, and that of IRI did not change. To the best of our
knowledge, this is the first report to estimate changes in
biomarkers associated with adipocyte function and insulin
and glucagon kinetics using the MTT after treatment with
dapagliflozin.
The glucose-lowering effects of dapagliflozin have been
confirmed in several clinical trials conducted in Japan and
overseas. In a dose determination study of drug naive
Japanese patients with T2DM, dapagliflozin 5 and
10 mg/day reduced HbA1c level by 0.41 and 0.45 %,
respectively, from baseline at 24 weeks after treatment
[12]. In another study in Japan that evaluated the add-on
effect of dapagliflozin to an existing antidiabetic agent,
dapagliflozin 5 mg/day for 12 weeks reduced HbA1c level
by approximately 0.6 % [13]. In our survey site, the HbA1c
Fig. 1 Changes in a glucose, b insulin, and c glucagon levels after the meal tolerance test
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values (average 7.4 %) where dapagliflozin was not added
were not changed in the same survey period. Our results
showed that adding dapagliflozin improved glycemic con-
trol at the same level of previous reports.
Insulin resistance and obesity are closely linked, and
obesity is known to be a risk factor for inadequate glycemic
control. Therefore, the importance of maintaining ideal
body weight is emphasized in the treatment of diabetes
mellitus. Among antidiabetic agents, GLP-1 receptor ago-
nists reduce body weight, but several antidiabetic agents
increase body weight while reducing glucose levels. In
general, SGLT2 inhibitors promote weight loss and,
indeed, dapagliflozin decreased body weight by 3.9 kg in
this study. Consistent with this, previous studies have
reported that dapagliflozin decreased body weight by
approximately 2 kg [12, 13]. Since glucose in urine is
cotransported with sodium ions via SGLT2, the inhibition
of SGLT2 suppresses reabsorption of water with sodium
ions, as well as the reabsorption of glucose. Water loss
leads to weight loss in the early phases of treatment with
SGLT2 inhibitors; however, weight loss during long-term
treatment with SGLT2 inhibitors appears to be related to a
loss of calories resulting from a reduction in available
glucose [14]. Recently, the incidence of diabetic ketoaci-
dosis (DKA) occurring in conjunction with SGLT-2 inhi-
bitor therapy has risen, with our results showing elevated
ketone bodies [15]. We need to pay attention to dehydra-
tion in order to prevent DKA.
Reduction of abdominal fat volume is considered an
essential element for weight loss therapy in obese patients.
Bolinder et al. evaluated changes in body composition
24 weeks after treatment with dapagliflozin 10 mg by
using dual energy X-ray absorptiometry, and reported a
2.08 kg reduction in weight, which was accompanied by a
decrease in total fat volume, abdominal fat volume, and
subcutaneous fat volume [16]. In another study, weight loss
with diet and exercise therapy in obese patients signifi-
cantly increased adiponectin levels and decreased PAI-1
levels [17, 18]. Given these findings from previous studies,
although body composition was not assessed in the present
study, it may be involved in the increase in adiponectin
levels and decrease in PAI-1 levels. Since adiponectin was
significantly associated with changes in HbA1c and body
weight, SGLT2 inhibitors may improve adipocyte function.
Adipocyte function is closely related to insulin resis-
tance. Thus, dapagliflozin may have mitigated insulin
resistance by improving adipocyte function. HOMA–IR
decreased slightly with dapagliflozin treatment, although
the change was not significant. Postprandial glucose levels
significantly decreased, but insulin release did not signifi-
cantly change after treatment with dapagliflozin. These
postprandial changes appear reasonable when considering
that the glucose-lowering effects of SGLT2 inhibitors do
not depend on the amount of insulin secretion [19, 20].
We found that glucagon levels increased during the
fasting phase, as well as after the MTT. Bonner et al.
reported that dapagliflozin promotes glucagon secretion
and hepatic gluconeogenesis in healthy mice [21], and also
found that SGLT2 inhibition by dapagliflozin increases
glucagon secretion, thereby mimicking the effects of low-
ering glucose levels, possibly through KATP channel acti-
vation and membrane repolarization, as reported by Zhang
et al. [22]. Little evidence is available to determine whether
treatment with SGLT2 inhibitors is associated with
increased glucagon secretion, and further studies will be
needed to address this issue.
From the physiological perspective, the mechanism by
which SGLT2 inhibitors lower glucose levels differs from
that achieved by restricting carbohydrate intake by diet.
Restricting carbohydrate intake by diet reduces the amount
of glucose absorbed by the digestive tract into the portal
vein. In contrast, SGLT2 inhibitors increase the amount of
glucose in urine by inhibiting the reuptake of glucose in the
renal tubule. It is unclear how these effects of SGLT2
inhibitors provide feedback to glucose metabolism. When
considering the physiological mechanism, since the source
of metabolism may shift from glucose to fat due to
reduction of glucose as an energy source, the level of
ketone bodies may increase [23]. Consistent with this, we
found an increase in ketone levels in our patients, although
there were no harmful effects from this increase. A pre-
vious study reported that an increase in 3-hydroxybutyric
acid was associated with tolerability to oxidative stress
[24]. Further studies will be needed to determine the sig-
nificance of increased ketone bodies induced by SGLT2
inhibitors.
4.1 Limitations
This study has several limitations worth noting. First, there
may have been selection bias given the small sample size
and the fact that patients were from one medical institution
specializing in diabetes treatment. In addition, the study
lacked a control group and participants received hetero-
geneity of concomitant glucose-lowering drugs; therefore,
application to actual clinical settings may be limited. A
large-scale, multicenter, controlled study will be needed to
better compare our data with data from other medical
settings. Second, important factors such as health behavior
were not evaluated. Such factors should also be evaluated
in future studies. Finally, 12 weeks is a relatively short
follow-up period. As a next step, cohort studies with longer
follow-up periods should be conducted in order to assess
long-term outcomes, including glycemic control.
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5 Conclusions
In this study, we found that treatment of obese T2DM
patients with dapagliflozin 5 mg once daily for 12 weeks
significantly reduced HbA1c and body weight to the same
level as previous reports. Although ketone bodies increased
significantly, CRP significantly decreased, and adiponectin
significantly increased. During the MTT, blood glucose
DAUC2 reduced significantly, but glucagon DAUC2
increased, and that of IRI did not differ. These findings
suggest that SGLT2 inhibitors may potentially improve
adipocyte function in treating obese T2DM patients.
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